Showing results (1091-1100 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|November 21, 2023
Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trialsAsif Muhammed, Christy Thomas, Vivekanandan Kalaiselvan, et al.Expert Opinion on Drug Safety|November 23, 2023
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancerIlana Schlam, Antonio Giordano, Sara M TolaneyExpert Opinion on Drug Safety|January 12, 2024
Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary interventionMuhammed Ibrahim Erbay, Nikolaos Pyrpyris, Shriraj Susarla, et al.Expert Opinion on Drug Safety|December 13, 2023
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)Roger S McIntyre, Rodrigo B Mansur, Joshua D Rosenblat, et al.Expert Opinion on Drug Safety|December 14, 2023
Comparative study on the occurrence of adverse effects in the concomitant use of azathioprine and aldehyde oxidase inhibitorsHinata Ueda, Katsuya Narumi, Shuho Asano, et al.Expert Opinion on Drug Safety|December 21, 2023
Safety and effectiveness of rasagiline in patients with Parkinson's disease in Japan: a post-marketing surveillance studyNobutaka Hattori, Mika Kajita, Shinji Fujimoto, et al.Expert Opinion on Drug Safety|December 19, 2023
Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety reviewFrancesco Locatelli, Ernesto Paoletti, Lucia Del VecchioExpert Opinion on Drug Safety|April 1, 2024
Safety profile of Helicobacter pylori eradication treatments: literature review and updated data of the European Registry on Helicobacter pylori management (Hp-EuReg)Irina Luzko, Olga P Nyssen, Leticia Moreira, et al.Expert Opinion on Drug Safety|March 30, 2024
Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting SystemDehua Zhao, Xiaoqing Long, Jisheng WangExpert Opinion on Drug Safety|March 18, 2024
Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance studyKangyuan Guo, Ganyi Wang, Li Zhang, et al.Pageof 282